When can we stop cabergoline treatment in prolactinomas?

Current Opinion in Endocrinology and Diabetes

Volumn 10, Issue 4, 2003, Pages 259-264

  Vitale, Giovanni ^a   Di Sarno, Antonella ^a   Rota, Francesca ^a   Lombardi, Gaetano ^a   Colao, Annamaria ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; PROLACTIN;

ANTINEOPLASTIC ACTIVITY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; CONGENITAL MALFORMATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLOW UP; GESTATIONAL AGE; HEADACHE; HUMAN; MEDICAL DECISION MAKING; NAUSEA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOSTATIC HYPOTENSION; PROLACTIN BLOOD LEVEL; PROLACTINOMA; PSYCHOSIS; REVIEW; SPONTANEOUS ABORTION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR VOLUME; VERTIGO; VISUAL FIELD DEFECT; VOMITING;

EID: 0242391976     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-200308000-00006     Document Type: Review

References (51)

1. Vance ML, Thorner MO: Prolactin: hyperprolactinemic syndromes and management. In: Textbook of endocrinology. Edited by DeGroot LJ. Philadelphia: WB Saunders; 1989:408-418.
2. Costello RT: Subclinical adenoma of the pituitary gland. Am J Pathol 1936, 12:205-216.
3. Burrow GN, Wortzman G, Rewcastle NB, et al.: Microadenomas of the pituitary gland and abnormal sellar tomograms in an unselected autopsy series. N Engl J Med 1980, 304:156-158.
4. Calle-Rodrigue RD, Giannini C, Scheithauer BW, et al.: Prolactinomas in male and female patients: a comparative clinicopathologic study. Mayo Clin Proc 1998, 731046-1052.
5. Delgrange E, Trouillas J, Maiter D, et al.: Sex-related difference in the growth of prolactinomas : a clinical and proliferation marker study. J Clin Endocrinol Metab 1997, 82:2102-2107.
6. Colao A, Sarno AD, Cappabianca P, et al.: Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol 2003, 148:325-323.
7. Colao A, Lombardi G: Growth hormone and prolactin excess. Lancet 1998, 352:1455-1461.
8. Cunnah D, Besser M: Management of prolactinomas. Clin Endocrinol 1991, 34:231-235.
9. Colao A, Annunziato L, Lombardi G: Treatment of prolactinomas. Ann Intern Med 1998, 30:452-459.
10. Molitch ME, Thorner MO, Wilson C: Therapeutic controversy: management of prolactinomas. J Clin Endocrinol Metab 1997, 82:996-1000.
11. Verhelst J, Abs R, Maiter D, et al.: Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 1999, 84:2518-2522.
12. Colao A, Di Sarno A, Landi ML, et al.: Macroprolactinoma shrinkage during cabergoline treatment is greater in naive than in patients pre-treated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab 2000, 85:2247-2252.
13. Cappabianca P, Lodrini S, Felisati G, et al.: Cabergoline-induced CSF rhinorrhea in patients with macroprolactinoma: report of three cases. J Endocrinol Invest 2001, 24:183-187.
14. Cappabianca P, Alfieri A, Colao A, et al.: Endoscopic endonasal transsphenoidal approach: an addition reason in support of surgery in the management of pituitary lesions. Skull Base Surg 1999, 9:109-117.
15. Cappabianca P, Alfieri A, Colao A, et al.: Endoscopic endonasal transsphenoidal surgery in recurrent and residual pituitary adenomas: technical note. Minim Invasive Neurosurg 2000, 43:38-43.
16. Webster J: A comparative review of the tolerability profiles of DA agonists in the treatment of hyperprolactinemia and inhibition of lactation. Drug Saf 1996, 14:228-238.
17. Serri O: Progress in the management of hyperprolactinemia. N Engl J Med 1994, 331:942-944.
18. Molitch ME: Medical treatment of prolactinomas. Endocrinol Metab Clin North Am 1999, 28:143-167.
19. Vance M, Evans W, Thorner M: Bromocriptine. Ann Intern Med 1984, 100:78-91.
20. Bevan JS, Webster J, Burke CW, et al.: Dopamine agonists and pituitary tumour shrinkage. Endocr Rev 1992, 13:220-240.
21. Molitch ME, Elton RL, Blackwell RE, et al.: Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab 1985, 60:698-705.
22. Webster J, Piscitelli G, Polli A, et al.: A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 1994, 331:904-909.
23. Colao A, De Rosa M, Sarnacchiaro F, et al.: Chronic treatment with CV 205-502 restores the gonadal function in hyperprolactinemic males. Eur J Endocrinol 1996, 135:548-552.
24. De Rosa M, Colao A, Di Sarno A, et al.: Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine. Eur J Endocrinol 1998, 138:286-293.
25. Colao A, Di Sarno A, Sarnacchiaro F, et al.: Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab 1997, 82:876-883.
26. Delgrange E, Maiter D, Donckier J: Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine. Eur J Endocrinol 1996, 134:454-456.
27. Biller BMK, Molitch ME, Vance ML, et al.: Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 1996, 81:2338-2343.
28. Ferrari CI, Abs R, Bevan JS, et al.: Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Clin Endocrinol (Oxf) 1997, 46:409-413.
29. Colao A, Di Sarno A, Landi ML, et al.: Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab 1997, 82:3574-3579.
30. Cannavo S, Curto L, Squadrito S, et al.: Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenomas. J Endocrinol Invest 1999, 22:354-359.
31. Di Sarno A, Landi ML, Cappabianca P, et al.: Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition and therapeutic strategy. J Clin Endocrinol Metab 2001, 86:5256-5261.
32. Liuzzi A, Oppizzi G: Microprolactinomas: why requiem for surgery? J Endocrinol Invest 1996, 19:196-198.
33. Johnston DG, Hall K, Kendall-Taylor P, et al.: Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas: studies with high-definition computerized tomography. Lancet 1984, 2:187-192.
34. Wang C, Lam KSL, Ma TC, et al.: Long-term treatment of hyperprolactinemia with bromocriptine: effect of drug withdrawal. Clin Endocrinol 1987, 27:363-371.
35. Van't Verlaat JW: Croughs RJ: Withdrawal of bromocriptine after long-term therapy for macroprolactinomas: effect on plasma prolactin and tumor size. Clin Endocrinol 1991, 34:175-178.
36. Moriando P, Travaglini P, Nissim M, et al.: Bromocriptine treatment of microprolactinomas: evidence of stable prolactin decrease after drug withdrawal. J Clin Endocrinol Metab 1985, 60:764-772.
37. Zarate A, Canales ES, Cano C, et al.: Follow-up of patients with prolactinoma after discontinuation of long-term therapy with bromocriptine. Acta Endocrinol 1983, 104:139-142.
38. Passos VQ, Souza JJS, Musolino NRC, et al.: Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal. J Clin Endocrinol Metab 2002, 87:3578-3582. An interesting study evaluating a long-term follow-up of prolactinomas after dopamine agonists withdrawal.
39. Rasmussen C, Bergh T, Wide L: Prolactin secretion and menstrual function after long-term bromocriptine treatment Fertil Steril 1987, 48:550-554.
40. Ferrari C, Paracchi A, Mattei A, et al.: Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol 1992, 126:589-594.
41. Di Sarno A, Landi ML, Marzullo P, et al.: The effect of quinagolide and cabergoline, two selective dopamine receptor type-2 agonists, in the treatment of prolactinomas. Clin Endocrinol (Oxf) 2000, 53:53-60.
42. Thorner MO, Perryman RL, Rogol AD, et al.: Rapid changes of prolactinoma volume after withdrawal and reinstitution of bromocriptine. J Clin Endocrinol Metab 1981, 53:480-483.
43. Orrego JJ, Chandler WF, Barkan AL: Rapid re-expansion of a macroprolactinoma after early discontinuation of bromocriptine. Pituitary 2000, 3:189-192.
44. Muratori M, Arosio M, Gambino G, et al.: Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. J Endocrinol Invest 1997, 20:537-546.
45. th Annual Meeting 2002, abstract OR 13-1.
46. Beltrame D, Longo M, Mazuè G: Reproductive toxicity of cabergoline in mice, rats, and rabbits. Reprod Toxicol 1996, 10:471-483.
47. Robert E, Musatti L, Piscitelli G, et al.: Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod Toxicol 1996, 10:333-337.
48. Ciccarelli E, Grottoli S, Razzore P, et al.: Long-term treatment with cabergoline a new long-lasting ergoline derivative in idiopathic or tumorous hyperprolactinemia and outcome of drug-induced pregnancy. J Endocrinol Invest 1997, 20:547-551.
49. Corenblum B, Donovan L: The safety of physiological estrogen plus progestin replacement therapy and with oral contraceptive therapy in women with pathological hyperprolactinemia. Fertil Steril 1993, 59:671-673.
50. Ricci E, Parazzini F, Motta T, et al.: Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reprod Toxicol 2002, 16:791-793.
51. Colao A, di Sarno A, Pivonello R, et al.: Dopamine receptor agonists for treating prolactinomas. Expert Opin Investig Drugs 2002, 11:787-800.